At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 559 enrolled
Drug / intervention
Orforglipron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
In Brief
A Phase 3 clinical trial evaluating Orforglipron and Placebo for Type 2 Diabetes. Completed, enrolled 559 participants across 89 sites in 6 countries.
Detailed Summary
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesChina, India, Japan, Mexico, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedAug 2023
Enrollment StartAug 2023
Primary CompletionApr 2025
TodayJul 2026
First PostedAug 2, 2023
Enrollment StartAug 9, 2023
Primary CompletionApr 3, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 2.9 years ago
Interventions
Orforgliprondrug
Administered orally
Placebodrug
Administered orally